KDKyle A. Davis

Kyle A. Davis

*This is an algorithmically generated author record based on publicly available information.

Kyle A. Davis has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lived Experience Expert, community engagement, policy, and health equity, diversity, and inclusion elements of the Bleeding Disorders Research Collaborative

    by Kyle A. Davis, Nathan Mermilliod, Jeremy Griffin, Samantha A. Carlson, Erin Burke Cirelli, Michelle Conde, Donna DiMichele, Alexis Dinno, Michael Glenzer, Roshni Kulkarni, et al.

    1. 1.1. In 2020, the U.S. National Bleeding Disorders Foundation (NBDF) embraced community-based participatory research (CBPR), in which the community and research team play equitable roles in ever...


  • Open Access

    The EnzySystem HemA, a novel point-of-care platform to measure FVIII activity and Thrombin Generation simultaneously: Qualitative usability evaluation (Preprint)

    by Aernoud Bavinck, Saskia E.M. Schols, Wilfred Teunissen, Amy Shapiro, M.A. Blijlevens Nicole, Kyle Davis, Waander van Heerde

    BACKGROUND Hemophilia A is an inherited bleeding disorder with an increased risk of excessive bleeding. People affected by hemophilia A with a severe bleeding phenotype are treated prophylactically with hemostatic agents. Monitoring treatment and adjusting it to the individual patient’s needs is complicated by the scarcity of laboratories equipped to perform relevant coagulation assays and the absence of point-of-care testing platforms. A novel near-patient testing platform called the EnzySystem HemA aims to address this issue by measuring Factor VIII activity and Thrombin Generation within one hour out of 100 µL of whole blood. OBJECTIVE This study assessed the usability of the EnzySystem HemA by healthcare professionals without prior training and gathered information on its perceived usability, effectiveness, usefulness, and acceptability. METHODS A qualitative, single-center formative usability assessment was performed. Seven healthcare providers participated, all unaffiliated with the EnzySystem’s developer (Enzyre). Participants included one pediatric hematologist, three (pediatric) nurses, and three (pediatric) nurse practitioners. Two of the participants also held management positions. Participants performed a FVIII activity assay with a mockup of the EnzySystem HemA and were interviewed about its acceptability, usability, effectiveness, and usefulness. Video recordings of the sessions were obtained with permission and subsequently reviewed to assess usability; thematic analysis was performed on the interview transcripts. RESULTS Five participants (71%, 5/7) successfully performed the FVIII activity assay as intended. Of the remaining two participants, one applied insufficient force when inserting the blood tube, while the other was unable to transfer the blood into the EnzySystem. This latter step caused difficulties in three other participants, however they completed it correctly. Five participants (71%, 5/7) did not dispose of the EnzySystem components as intended, primarily due to compatibility issues of the disposable parts with the inlet of US standard medical waste containers. Five themes were generated from the interviews: “Functional the way it is” focuses on the acceptance of the prototype despite suggestions for various improvements; “Utility through faster results and increased access” and “Potential for patient engagement” relate to the envisioned benefits of the platform; and “Financial investment and return” and “Ensuring accuracy” reflect on potential barriers for implementation. CONCLUSIONS Despite significant usability issues, the need for faster and more accessible testing led participants to conclude that the current platform was acceptable for use, provided that proof of assay accuracy was demonstrated. The results of this study will form the basis for further development of the EnzySystem HemA. The effectiveness of any updates will be evaluated in future usability studies, which will also include people with hemophilia A as participants. CLINICALTRIAL

  • Screening urinalysis demonstrates that haematuria is a frequent finding in persons with haemophilia treated at a paediatric haemophilia treatment centre

    by Kyle A. Davis, Joseph R. Stanek, Amy L. Dunn

    Introduction Haematuria is a recognized complication of haemophilia A and B (HA, HB). Adult persons with haemophilia (PWH) have a higher prevalence of renal disease than the general population. There is limited literature investigating the prevalence of haematuria in paediatric PWH. Aim Our paediatric haemophilia treatment centre (HTC) had previously used quality improvement methods to increase the frequency of screening urinalyses at annual comprehensive visits. We retrospectively reviewed the data collected to determine the prevalence of haematuria and explore for associations in those with haematuria. Methods Retrospective chart review to identify the frequency of haematuria on screening urinalysis in all male PWH >= 2 years old. Haematuria was defined as >= 3 red blood cells (RBCs) per high power field. Univariate logistic regression was performed to evaluate for associations with haematuria. Results A total of 93 patients met eligibility criteria. Sixty-seven with HA (11 mild, 17 moderate, 39 severe) and 26 with HB (three mild, 16 moderate, seven severe). Forty-two of ninety-three (45%) patients were identified as having haematuria (median RBCs 7, mean RBCs 332). Of those with haematuria, 76% were identified by screening UA, as opposed to clinical symptoms, and 52% had recurrent haematuria. Older age and HA were associated with an increased likelihood of haematuria. Conclusions Our study demonstrated that the prevalence of haematuria was high in PWH treated at our paediatric HTC. Future investigation is needed to determine the population-wide prevalence of haematuria in paediatric PWH and its impact on renal function.


  • Use of Cardiac MRI to Assess Antitumor Efficacy of Everolimus in Sporadic Cardiac Rhabdomyoma

    by Kyle A. Davis, Anudeep K. Dodeja, Abigail Clark, Kan Hor, Peter Baker, Linda H. Cripe, Timothy P. Cripe

    Cardiac rhabdomyoma is the most common neonatal cardiac tumor and is typically associated with tuberous sclerosis complex (TSC). Although these tumors may naturally regress, some patients require surgical resection because of cardiac instability. If not fully resected, patients may also require medical therapy to improve their hemodynamics. Everolimus, a mammalian target of rapamycin inhibitor, has shown promise in reducing rhabdomyoma in patients with TSC, but the drug’s impact in patients without TSC has not been reported. Monitoring of tumor response has typically been limited to echocardiograms, which is not ideal given inherent difficulties in three-dimensional measurements. We report a case of sporadic cardiac rhabdomyoma in a neonate treated with everolimus resulting in tumor regression as documented by cardiac MRI. While on everolimus, our patient had an increased incidence of a preexisting arrhythmia, which resolved with planned cessation of therapy, suggesting that close monitoring is imperative in patients with arrhythmia.